Regeneron Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Regeneron Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count).
Regeneron Pharmaceuticals: 280 sponsored US clinical trials, 61 recruiting.
Regeneron Pharmaceuticals sponsors 280 registered US clinical trials on ClinicalTrials.gov, 61 of them currently recruiting, and 151 completed. 83 of these trials are in Phase 3-4 (later-stage) and 174 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dermatitis, Atopic, with 6 trials.
Top-decile sponsor footprint
Regeneron Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#122 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
151 of 190 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
280 total, page 5 of 6
Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects
NCT02516618
Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)
NCT02379052
Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)
NCT02418754
Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip
NCT02447276
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
NCT02326220
Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
NCT02265952
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
NCT02383212
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
NCT02290951
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT02277769
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
NCT01997164
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT02277743
Study of REGN1193 in Patients With Type 2 Diabetes Mellitus
NCT02284425
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT02260986
Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)
NCT02210780
Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers
NCT02121080
Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500
NCT02107872
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
NCT02097524
Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
NCT02061865
Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)
NCT01979016
Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia
NCT01963598
Open-label Study of Dupilumab in Patients With Atopic Dermatitis
NCT01949311
Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
NCT01926782
Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects
NCT01922661
Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)
NCT01910220
An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193
NCT01933763
Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers
NCT01893528
Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT01859988
Study to Assess the Safety and Tolerability of Single Doses of REGN1500
NCT01749878
Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)
NCT01730053
Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)
NCT01722045
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
NCT01727869
Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)
NCT01730040
Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid Malignancies
NCT01688960
Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)
NCT01720576
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
NCT01709513
Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
NCT01521559
Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
NCT01576484
A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene
NCT01604824
A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)
NCT01507402
Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers
NCT01484600
Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares
NCT01459796
Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol
NCT01451645
Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema
NCT01363440
Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia
NCT01266876
Study of Nesvacumab (REGN910/ SAR307746)
NCT01271972
Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis
NCT01259323
Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers
NCT01197391
A Study of Tocilizumab in Patients With Rheumatoid Arthritis
NCT01187563
Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin
NCT01161082
Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers
NCT01074372
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 93 |
| Phase 2 | 81 |
| Phase 3 | 75 |
| Phase 4 | 8 |
What is open in the Regeneron Pharmaceuticals pipeline
61 recruiting of 280 indexed (22% open); 151 completed (54%).
Phase mix: 83 late (III/IV) vs 174 early (I/II) (early-phase heavy).
Top condition: Dermatitis, Atopic (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Regeneron Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 280 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
Regeneron Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 280 trials (± recruiting share)
- Boston Scientific Corporation · 280 trials · 8% recruiting
- Alcon Research · 275 trials · 2% recruiting
- Eisai · 287 trials · 2% recruiting
- SWOG Cancer Research Network · 270 trials · 10% recruiting
Sponsors near 22% open enrollment (± trial volume)
- AtriCure · 22% recruiting · 23 trials
- University of Colorado, Boulder · 22% recruiting · 69 trials
- University of Maryland, College Park · 22% recruiting · 46 trials
- Northwell Health · 22% recruiting · 370 trials
Related
What to do with this Regeneron Pharmaceuticals page
280 registered trials is a research-attention snapshot, not an endorsement of Regeneron Pharmaceuticals or any single study.
- 61 of Regeneron Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Dermatitis, Atopic is the condition Regeneron Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dermatitis, Atopic trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Regeneron Pharmaceuticals pipeline card: 280 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.